According to a recent LinkedIn post from Cooler Heads, the company is highlighting the role of former users of its Amma scalp cooling device who are now supporting new patients as advocates. The post describes a pathway from patient experience to peer support and invites prior Amma users to email the company to become Cooler Heads Patient Advocates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also reiterates that Amma is an FDA-cleared scalp cooling device aimed at helping minimize hair loss in adult cancer patients undergoing treatment for solid tumors. For investors, this emphasis on patient advocacy suggests Cooler Heads may be deepening patient engagement and community-building around its product, which could support brand loyalty, referrals, and potential utilization growth.
By encouraging past users to take on advocacy roles, the company appears to be cultivating a low-cost, patient-centric support infrastructure. If effective, such a program could enhance the perceived value of Amma within oncology practices and among patients, potentially strengthening Cooler Heads’ positioning in the scalp cooling segment and supporting longer-term revenue opportunities.